We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

A Look At The Legality Behind Daraprim's Price Spike

Law360, New York (September 30, 2015, 12:15 PM EDT) -- Turing Pharmaceuticals AG and its controversial CEO Martin Shkreli recently made headlines when Turing raised the price of its antiprotozal drug Daraprim (pyrimethamine) from $13.50 to $750 per tablet.[1] The price...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.